Browsing by author "Melcher, Alan"
Now showing items 21-40 of 61
-
FUME-TCRseq enables sensitive and accurate sequencing of the T-cell receptor from limited input of degraded RNA.
Baker, A-M; Nageswaran, G; Nenclares, P; Ronel, T; Smith, K; et al. (American Association for Cancer Research (AACR), 2024-03-14)Genomic analysis of the T-cell receptor (TCR) reveals the strength, breadth, and clonal dynamics of the adaptive immune response to pathogens or cancer. The diversity of the TCR repertoire, however, means that sequencing ... -
Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.
Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-24)Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ... -
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin, EC; Dillon, MT; Nenclares, P; Grove, L; Soliman, H; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell ... -
Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model.
Andreou, T; Williams, J; Brownlie, RJ; Salmond, RJ; Watson, E; et al. (BMJ PUBLISHING GROUP, 2021-01-01)Patients with glioblastoma (GBM) have a poor prognosis, and inefficient delivery of drugs to tumors represents a major therapeutic hurdle. Hematopoietic stem cell (HSC)-derived myeloid cells efficiently home to GBM and ... -
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
Young, K; Lawlor, RT; Ragulan, C; Patil, Y; Mafficini, A; et al. (BMJ PUBLISHING GROUP, 2020-09-03)OBJECTIVE: A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify ... -
Immunogenicity of self tumor associated proteins is enhanced through protein truncation.
Kottke, T; Shim, KG; Alonso-Camino, V; Zaidi, S; Maria Diaz, R; et al. (CELL PRESS, 2016-12-07)We showed previously that therapy with Vesicular Stomatitis Virus (VSV) expressing tumor-associated proteins eradicates established tumors. We show here that when cellular cDNA were cloned into VSV which retained their own ... -
Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy.
Nenclares, P; Bhide, SA; Sandoval-Insausti, H; Pialat, P; Gunn, L; et al. (ELSEVIER SCI LTD, 2020-05-01)BACKGROUND: Pre-clinical evidence suggests reduced efficacy of anticancer treatment in patients exposed to broad-spectrum antibiotics. It is hypothesised that this phenomenon may be explained by the effects of antibiotics ... -
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
McLaughlin, M; Patin, EC; Pedersen, M; Wilkins, A; Dillon, MT; et al. (NATURE PORTFOLIO, 2020-04-01)The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic ... -
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-03)Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ... -
Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients.
West, EJ; Scott, KJ; Tidswell, E; Bendjama, K; Stojkowitz, N; et al. (MDPI, 2022-04-27)Pexa-Vec is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable ... -
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton, E; Hassan, J; Chan Wah Hak, C; Sivamanoharan, N; Wilkins, A; et al. (FRONTIERS MEDIA SA, 2021-10-18)Cancer patients with low or absent pre-existing anti-tumour immunity ("cold" tumours) respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render these patients susceptible to ICPI, initiation ... -
Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer.
Harrington, KJ; Bhide, SA; Forster, MD; Good, JS; Gunn, L; et al. (2020-08) -
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson, A; West, EJ; Carmichael, J; Scott, KJ; Turnbull, S; et al. (AMER ASSOC CANCER RESEARCH, 2022-06-03)Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally ... -
On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.
Nenclares, P; Gunn, L; Soliman, H; Bover, M; Trinh, A; et al. (BMJ PUBLISHING GROUP, 2021-06-01)BACKGROUND: Previous studies have suggested that inflammatory markers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and fibrinogen) are prognostic biomarkers in patients with a variety of solid cancers, ... -
Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion.
Cockle, JV; Brüning-Richardson, A; Scott, KJ; Thompson, J; Kottke, T; et al. (CELL PRESS, 2017-06-16)Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumors with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via ... -
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
Annels, NE; Arif, M; Simpson, GR; Denyer, M; Moller-Levet, C; et al. (CELL PRESS, 2018-06-29)As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) ... -
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
Samson, A; Bentham, MJ; Scott, K; Nuovo, G; Bloy, A; et al. (BMJ PUBLISHING GROUP, 2018-03-01)OBJECTIVE: Oncolytic viruses (OVs) represent promising, proinflammatory cancer treatments. Here, we explored whether OV-induced innate immune responses could simultaneously inhibit HCV while suppressing hepatocellular ... -
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors.
Annels, NE; Simpson, GR; Denyer, M; Arif, M; Coffey, M; et al. (CELL PRESS, 2021-03-26)Prostate cancers are considered "cold" tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely ... -
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield, DC; Kyula, JN; Rosenfelder, N; Chao-Chu, J; Kramer-Marek, G; et al. (NATURE PUBLISHING GROUP, 2016-04-01)Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy ... -
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Kottke, T; Tonne, J; Evgin, L; Driscoll, CB; van Vloten, J; et al. (NATURE PORTFOLIO, 2021-03-26)In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors ...